Targeting Escherichia coli PBP1b using fragment-based approaches
使用基于片段的方法靶向大肠杆菌 PBP1b
基本信息
- 批准号:10217694
- 负责人:
- 金额:$ 20.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2023-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntibiotic ResistanceAntibioticsAntimicrobial ResistanceAutolysisBacteriaBacterial Antibiotic ResistanceBindingBiological AssayCarbapenemsCell DeathCell WallCenters for Disease Control and Prevention (U.S.)CephalosporinsComplementComplexCrystallizationDataDevelopmentDoseDrug TargetingEnterobacteriaceaeEscherichia coliEscherichia coli ProteinsExtended-spectrum β-lactamaseGenesGoalsHypersensitivityLabelLeadLibrariesLightLinkLuciferasesMeasurementMechanicsMediatingMembraneMicrobiologyMolecular ConformationMolecular WeightMonobactamsMutationNosocomial InfectionsOutcomePenicillin-Binding ProteinsPeptidesPeptidoglycanPeptidyltransferaseProtein InhibitionProteinsResistanceResistance developmentResortScanningSepsisShapesSiteStructureSystemTestingUp-RegulationUrinary tract infectionVDAC1 genebasebeta-Lactam Resistancebeta-Lactamasebeta-Lactamsbiophysical toolscarbapenem-resistant Enterobacteriaceaecrosslinkdesignefflux pumpfitnessglobal healthhigh rewardhigh riskinhibitor/antagonistmortalitynovelnovel strategiesnovel therapeutic interventionoverexpressionpathogenpathogenic bacteriaperiplasmresistance mechanismresponsescreeningsuccess
项目摘要
Penicillin-binding proteins (PBPs) are proven β-lactam drug targets yet resistance to β-lactam antibiotics,
such as carbapenems and cephalosporins, has resulted in a global health problem. In particular, extended-
spectrum β-lactamase (ESBL) producing or carbapenem-resistant Enterobacteriaceae, which includes
Escherichia coli, are serious threats and are often linked to hospital-acquired infections. Bloodstream
infections caused by these pathogens have a high mortality rate. β-lactam antimicrobial resistance
mechanism in E. coli are multiple and include, for example, the expression of β-lactamases that can degrade
β-lactams, deletion of porins, and the overexpression of efflux pumps. Resistance is developing even
against new β-lactam/β-lactamase inhibitor combinations. This alarming resistance spurs the need to
develop different mechanisms of PBP inhibition to break this resistance cycle.
PBP1b, one of the key PBPs in E. coli, has two peptidoglycan (PG)-related catalytic activities: a
transglycosylase activity and a transpeptidase activity. Both activities build the PG mesh that provides critical
mechanical strength and shape for bacteria. PBP1b is activated by LpoB binding to PBP1b, leading to a
conformational change that stimulates both activities of PBP1b. Our goal is to develop a novel approach to
inhibiting PBP1b, by targeting the activation of PBP1b by LpoB. Deletion of LpoB or mutations in LpoB
that disrupt PBP1b binding leads to hypersensitivity to certain β-lactam antibiotics.
Aim 1: We propose to develop inhibitors of PBP1b activation by screening and developing compounds
that bind to the PBP1b-recognition site on activator LpoB via a fragment-based structural approach. We will
use thermal shift and split luciferase complementation assays to screen fragment library compounds. Hits
from these orthogonal assays are further probed using dose-response measurements, biophysical tools,
and a TG activity assay testing for a decrease of LpoB-mediated activation of PBP1b.
Aim 2: Fragment hits will be targeted for crystallographic analysis in complex with LpoB. The combined
structural information, affinity, activity, and thermal shift data will be used to design novel LpoB-directed
inhibitors in an iterative fashion. Top lead compounds will advance to microbiological testing.
The successful completion of our comprehensive high-risk/high-reward PPI targeting approach will lead
to a new strategy of re-sensitizing PBP-targeting antibiotics, which is urgently needed in light of the
current antibiotic resistance problem. The LpoB:PBP1b system is conserved in Enterobacteriaceae so our
results could extend to other pathogens. Furthermore, the successful outcome of this proposal could lead
to a paradigm shift in antibiotic development, re-focusing efforts on targeting PPIs in bacterial pathogens.
青霉素结合蛋白(PBP)是β-内酰胺类药物的靶点,但对β-内酰胺类抗生素具有耐药性,
例如碳青霉烯类和头孢菌素类,已经导致了全球性的健康问题。特别是,扩展-
产超广谱β-内酰胺酶(ESBL)或对碳青霉烯类耐药的肠杆菌科,包括
大肠杆菌是严重的威胁,通常与医院获得性感染有关。血流
由这些病原体引起的感染具有高死亡率。β-内酰胺类抗生素耐药性
机制在E.大肠杆菌中的β-内酰胺酶是多种的,并且包括例如可以降解
β-内酰胺、孔蛋白缺失和外排泵过表达。抵抗正在发展,
针对新的β-内酰胺/β-内酰胺酶抑制剂组合。这种令人担忧的阻力促使人们需要
开发不同的PBP抑制机制来打破这种抗性循环。
PBP 1b是E.大肠杆菌,具有两种肽聚糖(PG)相关的催化活性:a
转糖基酶活性和转肽酶活性。这两项活动都构建了PG网格,
机械强度和细菌的形状。PBP 1b通过LpoB与PBP 1b结合而活化,导致
构象变化刺激PBP 1b的两种活性。我们的目标是开发一种新的方法,
通过LpoB靶向激活PBP 1b来抑制PBP 1b。LpoB缺失或LpoB突变
破坏PBP 1b结合导致对某些β-内酰胺抗生素的超敏反应。
目的1:我们计划通过筛选和开发化合物来开发PBP 1b活化抑制剂
其通过基于片段的结构方法与激活剂LpoB上的PBP 1b识别位点结合。我们将
使用热位移和裂解荧光素酶互补测定来筛选片段文库化合物。安打
从这些正交分析中进一步使用剂量-反应测量,生物物理工具,
以及TG活性测定法测试LpoB介导的PBP 1b活化的降低。
目的2:将片段命中作为与LpoB复合物的晶体学分析的目标。将合并的
结构信息、亲和力、活性和热位移数据将用于设计新的LpoB定向的
以迭代的方式抑制剂。顶级铅化合物将进入微生物检测。
我们全面的高风险/高回报PPI目标定位方法的成功完成将导致
一种新的策略,重新敏感的PBP靶向抗生素,这是迫切需要的,鉴于
抗生素耐药性问题。LpoB:PBP 1b系统在肠杆菌科中是保守的,因此我们的
结果可能会扩展到其他病原体。此外,这一提议的成功结果可能导致
到抗生素开发的范式转变,重新集中精力靶向细菌病原体中的PPI。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FOCCO VAN DEN AKKER其他文献
FOCCO VAN DEN AKKER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FOCCO VAN DEN AKKER', 18)}}的其他基金
Developing novel pyrazolidinone antibiotics targeting PBP3 to overcome resistance mechanisms
开发针对 PBP3 的新型吡唑烷酮抗生素以克服耐药机制
- 批准号:
10590839 - 财政年份:2023
- 资助金额:
$ 20.13万 - 项目类别:
Targeting Escherichia coli PBP1b using fragment-based approaches
使用基于片段的方法靶向大肠杆菌 PBP1b
- 批准号:
10374158 - 财政年份:2021
- 资助金额:
$ 20.13万 - 项目类别:
Small molecule inhibitors of lytic transglycosylase to potentiate beta-lactam antibiotics
裂解性转糖基酶小分子抑制剂可增强 β-内酰胺抗生素的作用
- 批准号:
10078254 - 财政年份:2020
- 资助金额:
$ 20.13万 - 项目类别:
CRYSTALLOGRAPHIC STUDIES OF ANTIBIOTIC RESISTANCE PROTEINS AND SIGNAL TRANSDUCTI
抗生素耐药蛋白和信号转导的晶体学研究
- 批准号:
8362188 - 财政年份:2011
- 资助金额:
$ 20.13万 - 项目类别:
CRYSTALLOGRAPHIC STUDIES OF ANTIBIOTIC RESISTANCE PROTEINS AND SIGNAL TRANSDUCTI
抗生素耐药蛋白和信号转导的晶体学研究
- 批准号:
8170149 - 财政年份:2010
- 资助金额:
$ 20.13万 - 项目类别:
CRYSTALLOGRAPHIC STUDIES OF ANTIBIOTIC RESISTANCE PROTEINS AND SIGNAL TRANSDUCTI
抗生素耐药蛋白和信号转导的晶体学研究
- 批准号:
7954491 - 财政年份:2009
- 资助金额:
$ 20.13万 - 项目类别:
CRYSTALLOGRAPHIC STUDIES OF ANTIBIOTIC RESISTANCE AND SIGNAL TRANSDUCTION
抗生素耐药性和信号转导的晶体学研究
- 批准号:
7726243 - 财政年份:2008
- 资助金额:
$ 20.13万 - 项目类别:
Mechanistic studies and inhibition strategies for antibiotic resistance
抗生素耐药性的机制研究和抑制策略
- 批准号:
7884373 - 财政年份:2007
- 资助金额:
$ 20.13万 - 项目类别:
Mechanistic studies and inhibition strategies for antibiotic resistance
抗生素耐药性的机制研究和抑制策略
- 批准号:
7658125 - 财政年份:2007
- 资助金额:
$ 20.13万 - 项目类别:
CRYSTALLOGRAPHIC STUDIES OF ANTIBIOTIC RESISTANCE AND SIGNAL TRANSDUCTION
抗生素耐药性和信号转导的晶体学研究
- 批准号:
7602310 - 财政年份:2007
- 资助金额:
$ 20.13万 - 项目类别:
相似海外基金
The effects of antibiotics to the transfer frequency of the antibiotic resistance genes and the evolution of high-level resistance.
抗生素对抗生素抗性基因转移频率和高水平抗性进化的影响。
- 批准号:
22K05790 - 财政年份:2022
- 资助金额:
$ 20.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
NEC05839 Chicken or the Egg: Is AMR in the Environment Driven by Dissemination of Antibiotics or Antibiotic Resistance Genes?
NEC05839 先有鸡还是先有蛋:环境中的抗菌素耐药性是由抗生素或抗生素抗性基因的传播驱动的吗?
- 批准号:
NE/N019687/2 - 财政年份:2019
- 资助金额:
$ 20.13万 - 项目类别:
Research Grant
Combating Antibiotic Resistance to Aminoglycoside Antibiotics through Chemical Synthesis
通过化学合成对抗氨基糖苷类抗生素的耐药性
- 批准号:
392481159 - 财政年份:2017
- 资助金额:
$ 20.13万 - 项目类别:
Research Fellowships
NEC05839 Chicken or the Egg: Is AMR in the Environment Driven by Dissemination of Antibiotics or Antibiotic Resistance Genes?
NEC05839 先有鸡还是先有蛋:环境中的抗菌素耐药性是由抗生素或抗生素抗性基因的传播驱动的吗?
- 批准号:
NE/N019687/1 - 财政年份:2016
- 资助金额:
$ 20.13万 - 项目类别:
Research Grant
Chicken or the Egg: Is AMR in the Environment Driven by Dissemination of Antibiotics or Antibiotic Resistance Genes?
先有鸡还是先有蛋:环境中的抗菌素耐药性是由抗生素或抗生素抗性基因的传播驱动的吗?
- 批准号:
NE/N019857/1 - 财政年份:2016
- 资助金额:
$ 20.13万 - 项目类别:
Research Grant
The SuDDICU study- A study of the impact of preventative antibiotics (SDD) on patient outcome and antibiotic resistance in the critically ill in intensive care
SuDDICU 研究 - 一项关于预防性抗生素 (SDD) 对重症监护病危患者的患者预后和抗生素耐药性影响的研究
- 批准号:
366555 - 财政年份:2016
- 资助金额:
$ 20.13万 - 项目类别:
Operating Grants
Chicken or the Egg: Is AMR in the Environment Driven by Dissemination of Antibiotics or Antibiotic Resistance Genes?
先有鸡还是先有蛋:环境中的抗菌素耐药性是由抗生素或抗生素抗性基因的传播驱动的吗?
- 批准号:
NE/N019717/1 - 财政年份:2016
- 资助金额:
$ 20.13万 - 项目类别:
Research Grant
The SuDDICU study- A study of the impact of preventative antibiotics (SDD) on patient outcome and antibiotic resistance in the critically ill in intensive care
SuDDICU 研究 - 一项关于预防性抗生素 (SDD) 对重症监护病危患者的患者预后和抗生素耐药性影响的研究
- 批准号:
361307 - 财政年份:2016
- 资助金额:
$ 20.13万 - 项目类别:
Operating Grants
Contamination status of antibiotics and antibiotic resistance genes (ARGs) in tropical Asian aquatic environments with artificial and natural disturbance
人工和自然干扰下亚洲热带水生环境中抗生素和抗生素抗性基因(ARG)的污染状况
- 批准号:
25257402 - 财政年份:2013
- 资助金额:
$ 20.13万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
RAPID: COLLABORATIVE RESEARCH: Fate and Transport of Antibiotics and Antibiotic Resistance Genes During Historic Colorado Flood
快速:合作研究:历史性科罗拉多洪水期间抗生素和抗生素抗性基因的命运和运输
- 批准号:
1402635 - 财政年份:2013
- 资助金额:
$ 20.13万 - 项目类别:
Standard Grant